Search Results
Your search for ,MbA matches 883 pages
Showing 651 - 7002016 Special Awards: Researchers and Scientists Recognized for Significant Contributions to Cancer Care
Researchers, patient advocates, and global oncology community leaders dedicated to enhancing cancer prevention, treatment, and patient care will be honored with ASCO’s highest honor, its Special Awards, during the 2016 ASCO Annual Meeting. Among this year’s awardees are a lung cancer luminary who...
AACR 2016: Cologuard Detected Colorectal Cancer in Previously Unscreened Patients
A noninvasive colorectal cancer-screening test detected the disease in patients who had previously avoided more invasive screening measures, according to research presented by Prince et al at the 2016 AACR Annual Meeting (Abstract LB-296). The study of nearly 400 patients revealed four patients...
Adjuvant Trastuzumab May Be Insufficiently Used in Older Women With Breast Cancer
Reeder-Hayes et al found that adjuvant trastuzumab (Herceptin) may be underused in older women with early-stage HER2-positive breast cancer and reported their study results in the Journal of Clinical Oncology. Adjuvant trastuzumab also was used less often in black women than in white women. Rates...
Boswellia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. We chose Boswellia for this issue because of its increasing use by patients with cancer....
AACR 2016: Report Identifies Considerations for Alternative Payment Models for Cancer Care
A roundtable convened by the Turning the Tide Against Cancer initiative, composed of a multidisciplinary group of stakeholders, put forth five policy considerations that are critical to ensuring the delivery of high-quality oncology care while supporting innovation. The report was published by...
ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer
Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young people in the United States—and millions worldwide—from life-threatening cancers, ASCO said April 11 in a policy statement. Published by Bailey et al in the Journal of Clinical Oncology,...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists would disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast...
ASCO Pledges to Advance Interoperability Among Health Information Systems
ASCO has joined members of the health-care community in pledging to the U.S. Department of Health and Human Services (HHS) to commit to principles that will advance interoperability among health information systems. A formal announcement of the initiative was delivered by HHS Secretary Sylvia M....
Clifford A. Hudis, MD, FACP, Named ASCO’s Next CEO
Clifford A. Hudis, MD, FACP, Chief of the Breast Medicine Service, Vice President for Government Relations, and Chief Advocacy Officer at Memorial Sloan Kettering Cancer Center (MSKCC), and Professor of Medicine at Weill Cornell Medical College, has been named the next Chief Executive Officer...
Clifford A. Hudis, MD, FACP, Named ASCO’s Next CEO
Clifford A. Hudis, MD, FACP, Chief of the Breast Medicine Service, Vice President for Government Relations, and Chief Advocacy Officer at Memorial Sloan Kettering Cancer Center (MSKCC), and Professor of Medicine at Weill Cornell Medical College, has been named the next Chief Executive Officer (CEO) ...
ASCO Issues Report on State of Cancer Care in America: 2016
The State of Cancer Care in America: 2016, published online in the Journal of Oncology Practice1 and presented earlier this month at a Congressional briefing in Washington, DC, is ASCO’s third annual assessment of national trends in cancer care delivery. The report highlights many promising cancer...
The Time Is Now for the Worldwide Cancer Community to Be Proactive
The ASCO Post recently spoke with nationally recognized surgical oncologist Chandrakanth Are, MBBS, MBA, FRCS, FACS, Jerald L & Carolynn J. Varner Professor of Surgical Oncology & Global Health; Vice Chair of Education; and Program Director, General Surgery Residency, University of Nebraska ...
Increased Travel Burden Decreases Likelihood of Receiving Radiation Therapy for Rectal Cancer Treatment
Increased travel distance to a cancer treatment facility negatively impacts the likelihood that patients with stage II/III rectal cancer will receive radiation therapy to treat their disease, according to a study analyzing 26,845 patient records from the National Cancer Data Base (NCDB) published...
Phone Triage System Offers Potential to Reduce Patient Visits to the Emergency Department for Cancer Treatment–Related Symptoms
A quality improvement initiative to reduce the reliance of patients on visits to the emergency department for treatment of side effects related to cancer treatment was reported to be highly effective, according to early findings from a new study. 1 The strategy, involving a telephone triage...
ASCO Report Finds U.S. Cancer Care System Ill-Equipped to Deliver New Advances to Patients
As the nation embarks on an ambitious “moonshot” to accelerate progress against cancer, our system for delivering today's cancer treatments must be better prepared to bring advances to all patients, warns a new report from ASCO. The State of Cancer Care in America: 2016, published...
ASCO Recommends Improvements to Medicare for Managing Multiple Chronic Conditions
ASCO has submitted comments to the U.S. Senate Finance Committee Chronic Care Working Group regarding the Bipartisan Chronic Care Working Group Policy Options document published in December 2015. The society commended the working group for its efforts to improve the Medicare program for...
ASCO Provides Support and Guidance for the White House Cancer Moonshot Initiative
Although President Richard Nixon signed the National Cancer Act in 1971, essentially declaring a war on cancer, the genesis of the idea had actually been born 2 years earlier, after the first landing on the moon set off a new era of scientific exploration and sparked a belief that any scientific...
2016 Quality Care Symposium: New Triage System Decreases Emergency Room Visits by Oncology Patients in Florida
A quality improvement initiative to reduce patients’ reliance on emergency room (ER) visits to treat cancer treatment side effects has shown to be highly effective, according to early findings from a new study. The strategy, involving a telephone triage service coupled with patient education, ...
Mistletoe
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
Candid Discussions on Living With and After Cancer at An Evening for Cancer Survivors and Caregivers
On January 14, 2016, the Cancer Survivorship Symposium opened with An Evening for Cancer Survivors and Caregivers, an event featuring networking, a panel discussion, and an open forum to share the challenges of living with or after a cancer diagnosis. The audience included Symposium attendees as...
ASCO Issues Policy Statement Calling for Improvements to Clinical Pathway Programs in Oncology
ASCO released a new policy statement with recommendations to ensure that clinical pathways in oncology promote—not hinder—the care of patients with cancer. Published by Zon et al in the Journal of Oncology Practice,1 the statement asserted that the way in which these treatment management tools in...
ASCO Praises President for White House’s Support of ‘Moonshot’ Initiative
On January 28, 2016, ASCO released the following statement by ASCO President Julie M. Vose, MD, MBA, FASCO: ASCO applauds President Obama for aligning the Administration’s full support behind Vice President Biden’s “moonshot” initiative to accelerate the discovery of new cancer treatments, as...
New AJCC Precision Medicine Guidelines Aimed at Improving Personalized Cancer Treatment Plans for Patients
A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes. These guidelines were...
ASCO Names Advance of the Year, Highlights Major Top Research Trends
Research is the bedrock of progress against cancer, and discoveries in cancer biology are moving from bench to bedside faster than ever. No recent advance has been more transformative than the rise of immunotherapy, particularly over the past year, making this treatment strategy ASCO’s Advance of...
ASCO Names Cancer Advance of the Year: Immunotherapy
At a Capitol Hill briefing today, ASCO announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy—along with almost 60 other important cancer research advances—are described in ASCO's just-released report, Clinical Cancer Advances 2016: ASCO's...
'Doctor, We Prayed for You'
A 70-year-old female patient underwent a cardiac procedure to repair her mitral valve, and at the same time, she also underwent a coronary artery bypass grafting. She had an uneventful course for the first four postoperative days. On the sixth postoperative day, she started complaining of abdominal ...
Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.
Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Next-Generation Once-Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily...
Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following...
Mary Lou Smith, JD, MBA, on the Value of NCCN Guidelines to Patients and Their Advocates
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
ASCO President-Elect Julie Vose, MD, MBA
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.
Evolution
Ten years ago, ASCO created the Journal of Oncology Practice to address a gap in the literature; there were no peer-reviewed journals dedicated to the practical issues of delivering quality oncology care. The original research and editorials published in JOP focus on care delivery topics such as...
Journal of Oncology Practice Increases Frequency, Adds Clinical Reviews
ASCO recently announced that the Journal of Oncology Practice (JOP) will be printed on a monthly basis and offer new resources to supply oncology professionals with cutting-edge information on cancer care delivery. Doubling its content, the expanded journal also features clinical information from a ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Afghanistan
The ASCO Post is pleased to introduce this special focus on the worldwide cancer burden, beginning in this issue with a close look at the cancer incidence and mortality rates in the United States. The aim of this special feature is to highlight the global cancer burden for various countries of the...
The New Frontiers of Breast Cancer
A seismic shift is underway in screening and treatment approaches for breast cancer. These changes are being fueled by studies showing that mammography in younger women may do more harm than good and that advances in genomic testing and a better understanding of the biology of breast cancers may...
ASCO Submits Comments to CMS on EHR Stage 3 of Meaningful Use and Modifications Final Rule
On December 15, ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s Electronic Health Record (EHR) Stage 3 of Meaningful Use and Modifications in 2015 through 2017. The Society’s comments provided recommendations to CMS regarding the implementation of...
Conquer Cancer Foundation Hosts Inaugural Scientific and Career Development Retreat
In October 2015, the Conquer Cancer Foundation of ASCO (CCF) hosted its first Scientific and Career Development Retreat at ASCO Headquarters in Alexandria, Virginia, for past recipients of the Young Investigator Award (YIA) and Career Development Award (CDA). The YIA provides funding to promising...
New Precision Medicine Guidelines Aimed at Improving Personalized Cancer Treatment Plans for Patients
A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes. These guidelines were...
Journal of Oncology Practice Goes to Monthly Distribution With New and Enhanced Resources
ASCO announced today that the Journal of Oncology Practice (JOP) will be printed on a monthly basis and offer new resources to supply oncology professionals with cutting-edge information on cancer care delivery. Doubling its content, the expanded journal also features clinical information from a...
ASCO Calls for Improvements to Clinical Pathway Programs in Oncology
ASCO released a new policy statement with recommendations to ensure that clinical pathways in oncology promote—not hinder—the care of patients with cancer. Published by Zon et al in the Journal of Oncology Practice, the statement asserts that the way in which these treatment management...
Bequest from Dr. Nora Janjan and Jack Calvin Supports Conquer Cancer Foundation’s Work in Palliative Care
For Nora Janjan, MD, MPSA, MBA, the practice of oncology is rooted in purpose, empathy, and trust. “You walk into the hospital and you know exactly why you’re there,” she says. “You are there to help patients and their loved ones through probably the most difficult experience that they will ever...
Conflicts of Interest in Health-care Reform?
Last year’s health-care reform legislation, the Patient Protection and Affordable Care Act, was designed to incrementally roll out major new bureaucratic entities, oversight, and mandates for the practice of medicine between its enactment and 2013, after the next presidential election. A new...
Rising Costs of Cancer Care: It's More Than Drugs
All parties—the government, payers, and consumers—agree that, left unchecked, rising health-care costs will eventually hamstring vital portions of our delivery system. For example, Medicare, which covers more than 50% of the nation’s patients with cancer, is marching headlong toward insolvency....
ASCO Connection Adds New Columnists, Launches Group Creation Option
ASCO’s professional networking site, ASCOconnection.org, continues to build depth in areas of interest to the oncology community, adding as its newest commentator ASCO President Michael P. Link, MD, the Lydia J. Lee Professor in Pediatric Oncology at Stanford University School of Medicine, as well...
SIDEBAR: A Snapshot of I-SPY 2
With principal investigator Laura Esserman, MD, MBA, of the University of California, San Francisco, and co–principal investigator Donald Berry, PhD, of MD Anderson Cancer Center, I-SPY 2 will screen up to 12 different drugs in neoadjuvant therapy for breast cancer over the course of the trial. In...
Can Bayesian Design Streamline Our Sluggish Clinical Trial System?
The randomized controlled clinical trial has long been the gold standard for new cancer drugs to demonstrate worthiness of FDA approval; however, many experts contend that that our method of bringing drugs to the market is plagued by undue costs, long delays, and overregulation. According to Donald ...
Oncology’s Only Benchmark Report, National Practice Benchmark, Is Now a Yearly JOP Supplement
Would it surprise you to learn that 40% of your peers in oncology who responded to a survey last year have a certified electronic medical record system in place? Or that 86% of them are in physician-owned practices? Or that the average number of full-time equivalent hematology/oncology physicians...
SIDEBAR: Key Dates in the Medicare Physician Reimbursement Saga
October 21, 2009: SB 1776 (“the Doc Fix”) is introduced in the Senate [but fails to pass] November 19, 2009: House of Representatives passes HR 3961 (the Medicare Physician Payment Reform Act) [but Senate fails to pass] December 19, 2009: Congress passes Department of Defense appropriations bill...
Medicare Reimbursement to Physicians: Déjà Vu All Over Again
In February 2011, The ASCO Post published an opinion piece (“Congress and the ‘Doctor Fix’: Looking Back, Looking Ahead”) about the ping-pong of legislative continuing resolutions to avert a 21.3% cut in physician reimbursement. These continuing resolutions were necessary because the Affordable...
Reflections from The ASCO Post
The editors gratefully acknowledge all contributors to The ASCO Post and thank the columnists who contributed to Volume 2, January–December 2011: Al B. Benson III, MD, FACP Richard Boxer, MD, FACS Carlton G. Brown, RN, PhD, AOCN Barrie R. Cassileth, PhD E. David Crawford, MD Emil J. Freireich, MD, ...
